Cell Cycle:干细胞因子与卵巢癌预后密切相关

2013-01-10 Cell Cycle 好医 Steven译

        耶鲁大学医学院研究人员近日发现了干细胞因子(可促进卵巢癌的发展)与卵巢癌患者预后之间的重要联系。研究为新型卵巢癌靶向疗法铺平了道路,相关研究成果于近日被发表在《细胞周期》(Cell Cycle)杂志上。    首席研究员、耶鲁大学医学院妇产与生殖科助理教授Yingqun Huang博士和她的同事们证实了两种概念之间联系,彻底颠覆

  干细胞

  

  耶鲁大学医学院研究人员近日发现了干细胞因子(可促进卵巢癌的发展)与卵巢癌患者预后之间的重要联系。研究为新型卵巢癌靶向疗法铺平了道路,相关研究成果于近日被发表在《细胞周期》(Cell Cycle)杂志上。 

  首席研究员、耶鲁大学医学院妇产与生殖科助理教授Yingqun Huang博士和她的同事们证实了两种概念之间联系,彻底颠覆了常规的癌症治疗方式。

  第一个概念是“癌症干细胞”。这一概念表明在每个肿瘤的中心部位都有一个很难识别的癌细胞群体,这些癌细胞实际上会促进大多数肿瘤的生长。根据这一概念我们可以预测,普通疗法通常能杀灭大部分肿瘤细胞,但却为癌症干细胞的继续生长留下了非常适宜的环境。

  第二个概念被称为“种子与土壤”。这一概念强调了肿瘤细胞微环境的重要作用,这种微环境是癌细胞生长和扩散所必须的。

  联合研究员、耶鲁癌症中心Nita J. Maihle博士介绍称:“这两种概念对于诸如卵巢癌等通常难以诊断和治疗的成人实体瘤的治疗来说具有特殊的意义。卵巢癌患者常常因肿瘤细胞产生抗性而受到疾病复发的困扰,并最终导致肿瘤生长失控甚至患者出现死亡。”

  研究中,Huang博士和同事们从分子角度定义了这两种概念在卵巢癌中的相互作用。他们利用复杂的基因排序方式证实了干细胞因子Lin28和信号传递分子BMP4(骨成型蛋白)之间的控制联系。

  研究人员表示:“最新的分子型卵巢癌预后数据支持了我们的研究发现,同时研究还发现肿瘤微环境在卵巢癌变过程中起了促进的作用。这些发现将有助于科学家研发出新型的靶向疗法。”


Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment

Abstract: 
Emerging evidence suggests that the tumor microenvironment plays a critical role in regulating cancer stem cells (CSCs) and tumor progression through both autocrine and paracrine signaling. Elevated production of bone morphogenetic proteins (BMPs) from human ovarian cancer cells and stroma has been shown to increase CSC proliferation and tumor growth. Here, we report that Lin28, a stem cell factor, binds to BMP4 mRNA in epithelial ovarian carcinoma cells, thereby promoting BMP4 expression at the post-transcriptional level. As co-expression of Lin28 and Oct4 (another stem cell factor) has been implicated in ovarian cancer CSCs, we also determined that high levels of Lin28 are associated with an unfavorable prognosis when co-expressed with high levels of Oct4. Together, these findings uncover a new level of regulation of BMP4 expression and imply a novel Lin28/Oct4/BMP4-mediated mechanism of regulating ovarian tumor cell growth, thus holding potential for the development of new strategies for the diagnosis and treatment of ovarian cancer.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958852, encodeId=bc3e19588526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 17 18:07:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868618, encodeId=e6a71868618e0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Sep 23 00:07:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809528, encodeId=1a50180952866, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Feb 19 07:07:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283562, encodeId=ca80128356279, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Jan 12 03:07:00 CST 2013, time=2013-01-12, status=1, ipAttribution=)]
    2013-09-17 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958852, encodeId=bc3e19588526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 17 18:07:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868618, encodeId=e6a71868618e0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Sep 23 00:07:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809528, encodeId=1a50180952866, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Feb 19 07:07:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283562, encodeId=ca80128356279, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Jan 12 03:07:00 CST 2013, time=2013-01-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958852, encodeId=bc3e19588526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 17 18:07:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868618, encodeId=e6a71868618e0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Sep 23 00:07:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809528, encodeId=1a50180952866, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Feb 19 07:07:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283562, encodeId=ca80128356279, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Jan 12 03:07:00 CST 2013, time=2013-01-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958852, encodeId=bc3e19588526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 17 18:07:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868618, encodeId=e6a71868618e0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Sep 23 00:07:00 CST 2013, time=2013-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809528, encodeId=1a50180952866, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Feb 19 07:07:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283562, encodeId=ca80128356279, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Jan 12 03:07:00 CST 2013, time=2013-01-12, status=1, ipAttribution=)]

相关资讯

Cancer:二甲双胍或可用于卵巢癌治疗

       梅奥诊所的一项研究显示,伴卵巢癌的糖尿病患者中,服用二甲双胍组同不服用二甲双胍组相比可获得更好的生存率。该研究的重要意义在于研究人员将现有药物用于不同的或新的疾病的治疗。        二甲双胍是一种治疗糖尿病的常用处方药,之前已有很多研究显示二甲双胍可用于其他癌症的治疗,梅奥的这项研究又将卵巢

Lancet Oncol:吸烟者卵巢癌风险与亚型有关

  8月3日,《柳叶刀·肿瘤学》(Lancet Oncol)在线发表英国一项荟萃分析显示:正在吸烟者卵巢癌的发生率较从不吸烟者轻微增加(RR=1.06,P=0.01),但黏液性卵巢肿瘤的发生率显著增加(RR=1.79,P<0.0001),其中近一半是边缘恶性肿瘤;子宫内膜样腺癌(P=0.001)和透明细胞癌(P=0.03)风险在吸烟者中反而有所降低;未发现浆液性卵巢癌与吸烟存在相关性(P

Cancer Res.:揭示卵巢癌获得性耐药机制

澳大利亚墨尔本的彼得麦卡勒姆癌症中心的癌症基因组学和遗传研究组负责人David Bowtell博士,和他的同事利用肿瘤样本进行研究,首次报道了高度恶性浆液性卵巢癌化疗耐药性的机制。 "高度恶性浆液性癌约占上皮侵入性卵巢癌死亡率的三分之二"Bowtell说,"我们试图发现从患者第一次接受手术和化疗,到肿瘤复发并最终发展为抵抗化疗,这一过程中的分子变化。" 研究人员分析了个别病人转移病灶和22例

PLoS ONE:筛选FMR1基因突变更易检测卵巢癌和乳腺癌风险

研究人员开展一项基因突变研究,这些突变提高妇女患上乳腺癌和卵巢癌的几率。他们的研究发现可能有助于开发出更便宜和更容易的方法来筛选乳腺癌和卵巢癌。此外,这些令人吃惊的研究发现可能也解释着携带这些乳腺癌突变的人胚胎如何能够存活下来。相关研究于近期刊登在PLoS ONE期刊上。 已知妇女的乳腺癌和卵巢癌易感基因BRCA1和BRCA2(BRCA1/2)能够被用来预测她们患上这两种癌症的风险。当基因BRC

Clini Cancer Res:抵御卵巢癌的新型药物lurbinectedin(PM01183)

    近日,刊登在国际杂志Clinical Cancer Research上的一项多学科研究中,来自Bellvitge生物研究所和加泰罗尼亚肿瘤研究所的研究人员开发出了一种新型药物,其可以在特定动物模型中检测药物对顺铂耐药的卵巢癌的效果。     将人类的肿瘤组织植入到裸鼠中相应器官产生的部位,称为正位植入;这种方式可以产生组织学和遗

Nature:PPM1D基因变异或提示患癌

     近日,英国癌症研究院(ICR)的一个研究团队发现,PPM1D基因出现变异可增加乳腺癌和卵巢癌的风险。研究人员表示,这或能成为未来相关疗法的靶向作用目标,为预防提供了潜在指导方向。   出现PPM1D基因变异的女性患乳腺癌和卵巢癌的风险会上升20个百分点,而与普通人相比,其患乳腺癌和卵巢癌的风险分别是他们的2倍和10多倍。   这项于本周发表在《自然》杂志上的研究显